Zydus Lifesciences’ Verapamil Approval Analyzed

Zydus Lifesciences has just gotten the green light from the US Food and Drug Administration (USFDA) to sell Verapamil Hydrochloride Extended-Release Tablets. These tablets come in strengths of 120 mg, 180 mg, and 240 mg. They’re a copy of a medicine already used to treat high blood pressure and lower the chance of serious heart problems like strokes and heart attacks.

Key Points

• Zydus gained USFDA approval for Verapamil Hydrochloride ER tablets.
• Tablets available in 120mg, 180mg, and 240mg strengths.
• Treats high blood pressure, reduces cardiovascular risk.
• US market sales reach $24.5 million annually.
• Zydus’ approval count rises to 428 ANDAs.
• Company’s net profit jumped 38.12% in Q2 FY26.

These new tablets will be made at Zydus’ factory in Baddi, Himachal Pradesh. The company already sells a lot of similar medicines and this approval brings their total to 428.

According to market data, Verapamil Hydrochloride ER Tablets are selling really well – about $24.5 million each year in the United States. This shows there’s a big demand for this type of medicine.

Zydus Lifesciences is a big company focused on making and selling medicines all over the world. They are constantly trying to find new ways to help people stay healthy. They make more than 27,000 medicines yearly.

Their profits have recently gone up a lot – by 38.12% – showing that their business is doing well. This increase in revenue to Rs 6,037.9 crore highlights their growing success.

“This approval reinforces our commitment to delivering essential medicines to patients worldwide, fostering healthier lives.”